Io Therapeutics, Inc. Announces Initiation of Dosing in a Phase II Clinical Trial of IRX4204 in Patients With Advanced Prostate Cancer
06. Oktober 2011 11:00 ET
|
Io Therapeutics, Inc.
SANTA ANA, CA--(Marketwire - Oct 6, 2011) - Io Therapeutics, Inc. announced today initiation of dosing in a phase II clinical trial with its experimental cancer therapeutic, IRX4204, in patients...